Moderna, Inc. — Director's Dealing 2020

Mar 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-02-28

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-28	Common Stock	S	10000	$23.38	Disposed	84770	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-28	Stock Option (Right to Buy)	$25.93	A	161120	Acquired	2030-02-28	Common Stock (161120)	Direct
2020-02-28	Restricted Stock Units	$0	A	28924	Acquired		Common Stock (28924)	Direct

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F3: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.